Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
RADIANT
1 other identifier
observational
461
1 country
11
Brief Summary
The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2023
Shorter than P25 for all trials
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2023
CompletedFirst Posted
Study publicly available on registry
March 20, 2023
CompletedStudy Start
First participant enrolled
November 9, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 2, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 2, 2024
CompletedAugust 27, 2026
August 1, 2026
10 months
March 8, 2023
August 26, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Locoregional recurrence
To evaluate the effectiveness of the extreme hypofractionation scheme, in 5 fractions of 5.2 Gy, in women with breast cancer
18 months
Eligibility Criteria
Women with breast cancer undergoing radiotherapy with extreme hypofractionation.
You may qualify if:
- Women over 18 years old;
- Diagnosis of breast cancer of any molecular subtype;
- Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;
- Treated from December/2019 onward;
- With clinical and treatment data available in medical records.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
ICC - Instituto do Câncer do Ceará
Fortaleza, Ceará, 60.430-230, Brazil
Hospital Sírio-Libanês DF
Brasília, Federal District, 70.200-730, Brazil
Hospital Márcio Cunha da Fundação São Francisco Xavier (HMC-FSFX)
Ipatinga, Minas Gerais, 35.160-158, Brazil
Oncominas - Clínica de Oncologia no Sul de Minas
Pouso Alegre, Minas Gerais, 37.554-216, Brazil
Real Hospital Português de Beneficência em Pernambuco
Recife, Pernambuco, 50.030-230, Brazil
Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)
Rio de Janeiro, Rio de Janeiro, 22.793-080, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, São Paulo, 14.015-010, Brazil
Hospital Sírio-Libanês SP
São Paulo, São Paulo, 01.308-050, Brazil
HAOC - Hospital Alemão Oswaldo Cruz
São Paulo, São Paulo, 01.323-020, Brazil
BP - A Beneficência Portuguesa de São Paulo
São Paulo, São Paulo, 01.323-030, Brazil
A.C. Camargo Cancer Center
São Paulo, São Paulo, 01.509-001, Brazil
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gustavo Nader Marte
Latin American Cooperative Oncology Group
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 8, 2023
First Posted
March 20, 2023
Study Start
November 9, 2023
Primary Completion
September 2, 2024
Study Completion
September 2, 2024
Last Updated
August 27, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share